Federal Circuit backs Aveva in ZTlido patent dispute, clearing 180-day launch window

The appeals court upheld a Florida district court finding that Aveva's proposed generic lidocaine topical system 1.8% does not infringe three Scilex patents, removing a key barrier to an imminent commercial launch.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.